The role of aflibercept in the management of diabetic macular edema.
Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized the management of DME over the past decade with superior outcomes compared to laser therapy. This review summarizes the pathophysiology and available treatment options for the management of DME, with an emphasis on the efficacy and safety profile of a single particular intravitreal antivascular endothelial growth factor agent, aflibercept.
Sydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia ; Save Sight Institute, University of Sydney, Sydney, NSW, Australia.
Andrew A
AA
Chang
Sydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia.
Thomas
T
Hong
Sydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia.
Shaun Y
SY
Ewe
Sydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia.
Bobak
B
Bahrami
Sydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia ; Save Sight Institute, University of Sydney, Sydney, NSW, Australia.
Geoffrey K
GK
Broadhead
D000328:Adult; D000818:Animals; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor
aflibercept; diabetic macular edema